Wynzora
Wynzora

47.43
Topical application targets epidermal irritation and helps with the restoration of a balanced skin barrier.


Category
Availability
In Stock
Delivery Time
Airmail (14-21 days) | Trackable (5-9 days)
Shipped in a discreet, unmarked envelope with all required documents enclosed.

Product Sheet

Active Ingredient(s)
Betamethasone dipropionate, Calcipotriene
Product Origin
Generic Brand
Product Manufacturer
MC2 Therapeutics
Product Form
Cream
Regulatory Classification
Rx
Primary Category
Skin Care
Product Category
Corticosteroid/Vitamin D Analogue Combination
Pharmacological Class
Antipsoriatic Combination
Clinical Indications
Manufacturer Description
Utilized for plaque psoriasis to manage skin cell growth and support inflammation reduction.
Mechanism of Action
Calcipotriene normalizes the rate of skin cell production. Betamethasone suppresses the localized immune response and swelling. Together, they clear psoriatic plaques more effectively than either ingredient alone.
Route of Administration
Topical
Onset Time
1–2 weeks
Duration
12–24 hours
Contraindications
Hypercalcemia, Atrophy of the skin, Hypersensitivity to any component
Severe Adverse Events
Hypercalcemia, Adrenal suppression, Anaphylaxis — requires immediate medical attention
Common Side Effects
Burning, Itching, Redness
Uncommon Side Effects
Skin thinning, Folliculitis, Skin dryness
Drug Interactions
Alcohol
Pregnancy Safety Warnings
FDA Category C: Use with caution. Breastfeeding: Use only if clearly needed.
Age Restrictions
Safety and efficacy established in adults.
Storage Guidelines
Store at room temperature; do not freeze.
Related Products
Daivobet, Enstilar, Diprosone
Information related to Wynzora is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
Categories
How to purchase Mental Illness - Strattera Generic